Accentia Strikes $1.25M Deal To End Investors’ Vaccine Suit

An Accentia Biopharmaceuticals Inc. subsidiary agreed Friday to pay $1.25 million to settle a putative securities class action in Florida federal court accusing the company of lying to investors about the performance of a non-Hodgkin’s lymphoma treatment vaccine in development that artificially inflated both companies’ stock prices.